Get the Stockscreener App
19.15
1.79%
-0.35
Fulgent Genetics Inc stock is traded at $19.15, with a volume of 374.98K.
It is down -1.79% in the last 24 hours and up +28.52% over the past month.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
See More
Previous Close:
$19.50
Open:
$19.5
24h Volume:
374.98K
Relative Volume:
0.61
Market Cap:
$543.87M
Revenue:
$320.35M
Net Income/Loss:
$-75.01M
P/E Ratio:
-7.9948
EPS:
-2.3953
Net Cash Flow:
$-113.17M
1W Performance:
+5.57%
1M Performance:
+28.52%
6M Performance:
-31.09%
1Y Performance:
-8.02%
1-Day Range:
$18.65
$19.50
1-Week Range:
$17.62
$19.93
52-Week Range:
$13.46
$31.04
Fulgent Genetics Inc Stock (FLGT) Company Profile
Name
Fulgent Genetics Inc
Sector
Industry
Phone
626-350-0537
Address
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLGT
Fulgent Genetics Inc
|
19.15 | 553.81M | 320.35M | -75.01M | -113.17M | -2.3953 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Upgrade | UBS | Neutral → Buy |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-18-22 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Feb-04-22 | Resumed | Piper Sandler | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Underperform |
| Jan-08-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-20-20 | Initiated | Oppenheimer | Outperform |
| May-29-20 | Initiated | BTIG Research | Buy |
| Nov-05-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Mar-01-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Nov-07-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Fulgent Genetics Inc Stock (FLGT) Latest News
How The Fulgent Genetics (FLGT) Investment Story Is Evolving With Recent Developments - Yahoo Finance
How Fulgent Genetics Inc. (FLGT) Affects Rotational Strategy Timing - Stock Traders Daily
Fulgent Genetics CSO Gao Hanlin sells $30,190 in stock - Investing.com
Fulgent Genetics (NASDAQ: FLGT) insider sale covers RSU taxes - Stock Titan
Fulgent Genetics (FLGT) CFO reports tax withholding of vested RSU shares - Stock Titan
Fulgent Genetics (FLGT) CSO sells 1,688 shares to cover RSU tax - Stock Titan
Fulgent (NASDAQ: FLGT) CEO RSU vest triggers 4,392-share tax withholding - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) Form 144 lists 45,304 vested shares; small prior sale - Stock Titan
Fulgent Presents Updated Phase 2 FID-007 + Cetuximab Data at ASCO Showing 61.9% ORR - TradingView
Fulgent Genetics (FLGT) Presents Promising Data on Head and Neck Cancer Treatment - GuruFocus
Strong FID-007 Phase 2 results for Fulgent Genetics (NASDAQ: FLGT) - Stock Titan
Fulgent Presents Updated FID-007 Data at ASCO 2026 - The Joplin Globe
Fulgent Genetics COO Jian Xie sells $21,137 in company stock By Investing.com - Investing.com Australia
Fulgent Genetics COO Jian Xie sells $21,137 in company stock - Investing.com
Fulgent Genetics (NASDAQ: FLGT) exec sells shares for tax withholding - Stock Titan
[Form 4] Fulgent Genetics, Inc. Insider Trading Activity - Stock Titan
Fulgent Genetics (FLGT) CSO sells 945 shares to cover tax obligations - Stock Titan
Ming Hsieh (FLGT) reports 32% Fulgent Genetics stake and major share pledges - Stock Titan
Fulgent Genetics (FLGT) CEO reports RSU tax withholding and large trust holdings - Stock Titan
Fulgent Genetics (FLGT) price target decreased by 28.85% to 18.87 - MSN
(FLGT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Law firm investigates Fulgent Genetics for possible securities law violations after revenue miss. - Pluang
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics - GlobeNewswire
Fulgent Genetics Presents Promising Phase 2 FID-007 & Cetuximab Data for Head and Neck Cancer at ASCO 2026 - Minichart
Fulgent reports interim data for cancer drug FID-007 trial By Investing.com - Investing.com Australia
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting - BioSpace
Fulgent reports interim data for cancer drug FID-007 trial - Investing.com
Fulgent Announces ASCO Rapid Oral Abstract Showing 60% ORR, 7.2‑mo mPFS for FID-007 plus Cetuximab - TradingView
Fulgent (NASDAQ: FLGT) reports 60% ORR in Phase 2 FID-007 cancer trial - Stock Titan
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach - GlobeNewswire
Fulgent Genetics targets wider engagement at APG2026 San Diego exhibit fair - Traders Union
FLGT Stock Chart | FULGENT GENETICS INC (NASDAQ:FLGT) - ChartMill
Fulgent Genetics (FLGT) director receives stock units and 8,426-share option grant - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) director receives 11,117 RSUs - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) director awarded 11,117 restricted stock units - Stock Titan
Fulgent Genetics Shareholders Approve New 2026 Equity Plan - TipRanks
Fulgent Genetics (NASDAQ: FLGT) wins stockholder approval for 2026 equity plan - Stock Titan
ETFs Investing in Fulgent Genetics, Inc. Stocks - TradingView
Responsive Playbooks and the FLGT Inflection - Stock Traders Daily
Fulgent Genetics infertility test panels broaden to cover over 140 genes for females and 160 for males - Traders Union
TradingKey - TradingKey
LA500 2026: Ming Hsieh - Los Angeles Business Journal
Fulgent Genetics (NASDAQ:FLGT) Stock Passes Below Fifty Day Moving AverageHere's Why - MarketBeat
Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Wall Street Zen - MarketBeat
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - The Globe and Mail
Fulgent Genetics Inc Stock (FLGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fulgent Genetics Inc Stock (FLGT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gao Hanlin | Chief Scientific Officer |
Jun 02 '26 |
Sale |
17.89 |
1,688 |
30,191 |
990,374 |
2.13%
2.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):